Inflammatory and Oxidative Pathways Are New Drug Targets in Multiple Episode Schizophrenia and Leaky Gut, Klebsiella Pneumoniae, and C1q Immune Complexes Are Additional Drug Targets in First Episode Schizophrenia

Overview

Journal Mol Neurobiol

Specialties Molecular Biology
Neurology

Date 2021 Mar 6

PMID 33675500

Citations 23

Authors

Michael Maes

Aristo Vojdani

Sunee Sirivichayakul

Decio S Barbosa

Buranee Kanchanatawan

Affiliations

Soon will be listed here.

Abstract

Breakdown of paracellular and vascular pathways and activated neuroimmune and oxidative pathways was established in (deficit) schizophrenia. The aim of this study was to delineate (a) the differences in these pathways between stable-phase, first (FES) and multiple (MES) episode schizophrenia and (b) the pathways that determine the behavioral-cognitive-physical-psychosocial (BCPS) deterioration in FES/MES. This study included 21 FES and 58 FES patients and 40 healthy controls and measured indicants of serum C1q circulating immune complexes (CIC), leaky gut, immune activation, and oxidative stress toxicity (OSTOX). We constructed a BCPS-worsening index by extracting a latent vector from symptomatic, neurocognitive, and quality of life data. FES was associated with higher IgA CIC-C1q, IgA directed to cadherin, catenin, and plasmalemma vesicle-associated protein, and IgA/IgM to Gram-negative bacteria as compared with FES and controls. In FES patients, the BCPS-worsening score was predicted (48.7%) by IgA to Klebsiella pneumoniae and lowered paraoxonase 1 activity. In MES patients, the BCPS-worsening score was explained (42.7%) by increased tumor necrosis factor-α, OSTOX, and number of episodes. In schizophrenia, 34.0% of the variance in the BCPS-worsening score was explained by IgA to K. pneumoniae, OSTOX, and number of episodes. Increased IgA to K. pneumoniae was the single best predictor of residual psychotic symptoms in FES and MES. This study delineated different mechanistic processes in FES, including breakdown of adherens junctions, bacterial translocation, and IgA CIC-C1q formation, and MES, including immune and oxidative neurotoxic pathways. FES and MES comprise different staging subtypes, i.e., FES and MES with and without worsening.

Citing Articles

Bacillus coagulans alleviates hepatic injury caused by Klebsiella pneumoniae in rabbits.

Chen X, Wei W, Yang F, Wang J, Lv Q, Liu Y PLoS One. 2025; 20(1):e0317252.

PMID: 39792896 PMC: 11723646. DOI: 10.1371/journal.pone.0317252.

Interaction between serum inflammatory cytokines and brain-derived neurotrophic factor in cognitive function among first-episode schizophrenia patients.

Cui L, Cai L, Na W, Jia R, Zhu J, Pan X World J Psychiatry. 2024; 14(12):1804-1814.

PMID: 39704351 PMC: 11622020. DOI: 10.5498/wjp.v14.i12.1804.

Loss of C1q alters the auditory brainstem response.

Chokr S, Bui-Tran A, Cramer K Front Cell Neurosci. 2024; 18:1464670.

PMID: 39416682 PMC: 11480778. DOI: 10.3389/fncel.2024.1464670.

Identification of Immune-Related Gene Signature in Schizophrenia.

Wu Y, Wang Z, Hu H, Wu T, Alabed A, Sun Z Actas Esp Psiquiatr. 2024; 52(3):276-288.

PMID: 38863043 PMC: 11190455. DOI: 10.62641/aep.v52i3.1648.

The Gold Standard Diagnosis of Schizophrenia is Counterproductive: Towards Quantitative Research and Diagnostic Algorithmic Rules (RADAR) and their Derived Qualitative Distinct Classes.

Maes M Curr Top Med Chem. 2024; 24(20):1799-1815.

PMID: 38644707 DOI: 10.2174/0115680266295129240415120646.

References

Maes M, Vojdani A, Geffard M, Moreira E, Barbosa D, Michelin A . Schizophrenia phenomenology comprises a bifactorial general severity and a single-group factor, which are differently associated with neurotoxic immune and immune-regulatory pathways. Biomol Concepts. 2019; 10(1):209-225. DOI: 10.1515/bmc-2019-0023. View

Kanchanatawan B, Sriswasdi S, Maes M . Supervised machine learning to decipher the complex associations between neuro-immune biomarkers and quality of life in schizophrenia. Metab Brain Dis. 2018; 34(1):267-282. DOI: 10.1007/s11011-018-0339-7. View

Maes M, Sirivichayakul S, Matsumoto A, Michelin A, de Oliveira Semeao L, de Lima Pedrao J . Lowered Antioxidant Defenses and Increased Oxidative Toxicity Are Hallmarks of Deficit Schizophrenia: a Nomothetic Network Psychiatry Approach. Mol Neurobiol. 2020; 57(11):4578-4597. DOI: 10.1007/s12035-020-02047-5. View

Kanchanatawan B, Hemrungrojn S, Thika S, Sirivichayakul S, Ruxrungtham K, Carvalho A . Changes in Tryptophan Catabolite (TRYCAT) Pathway Patterning Are Associated with Mild Impairments in Declarative Memory in Schizophrenia and Deficits in Semantic and Episodic Memory Coupled with Increased False-Memory Creation in Deficit.... Mol Neurobiol. 2017; 55(6):5184-5201. DOI: 10.1007/s12035-017-0751-8. View

Kanchanatawan B, Sriswasdi S, Thika S, Sirivichayakul S, Carvalho A, Geffard M . Deficit schizophrenia is a discrete diagnostic category defined by neuro-immune and neurocognitive features: results of supervised machine learning. Metab Brain Dis. 2018; 33(4):1053-1067. DOI: 10.1007/s11011-018-0208-4. View

Kanchanatawan B, Sriswasdi S, Thika S, Stoyanov D, Sirivichayakul S, Carvalho A . Towards a new classification of stable phase schizophrenia into major and simple neuro-cognitive psychosis: Results of unsupervised machine learning analysis. J Eval Clin Pract. 2018; 24(4):879-891. DOI: 10.1111/jep.12945. View

Kanchanatawan B, Maes M . The Effects of Tryptophan Catabolites on Negative Symptoms and Deficit Schizophrenia are Partly Mediated by Executive Impairments: Results of Partial Least Squares Path Modeling. CNS Neurol Disord Drug Targets. 2018; 17(6):473-486. DOI: 10.2174/1871527317666180702160921. View

Kirkpatrick B, Buchanan R, McKenney P, Alphs L, Carpenter Jr W . The Schedule for the Deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res. 1989; 30(2):119-23. DOI: 10.1016/0165-1781(89)90153-4. View

Smith R, Maes M . The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med Hypotheses. 1995; 45(2):135-41. DOI: 10.1016/0306-9877(95)90062-4. View

10.

Maes M, DeLange J, Ranjan R, Meltzer H, Desnyder R, Cooremans W . Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res. 1997; 66(1):1-11. DOI: 10.1016/s0165-1781(96)02915-0. View

11.

Roomruangwong C, Noto C, Kanchanatawan B, Anderson G, Kubera M, Carvalho A . The Role of Aberrations in the Immune-Inflammatory Response System (IRS) and the Compensatory Immune-Regulatory Reflex System (CIRS) in Different Phenotypes of Schizophrenia: the IRS-CIRS Theory of Schizophrenia. Mol Neurobiol. 2019; 57(2):778-797. DOI: 10.1007/s12035-019-01737-z. View

12.

Maes M, Meltzer H, Bosmans E . Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand. 1994; 89(5):346-51. DOI: 10.1111/j.1600-0447.1994.tb01527.x. View

13.

Maes M, Meltzer H, Buckley P, Bosmans E . Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. Eur Arch Psychiatry Clin Neurosci. 1995; 244(6):325-9. DOI: 10.1007/BF02190412. View

14.

Noto C, Ota V, Gouvea E, Rizzo L, Spindola L, Honda P . Effects of risperidone on cytokine profile in drug-naïve first-episode psychosis. Int J Neuropsychopharmacol. 2014; 18(4). PMC: 4360233. DOI: 10.1093/ijnp/pyu042. View

15.

Maes M, Sirivichayakul S, Matsumoto A, Maes A, Michelin A, de Oliveira Semeao L . Increased Levels of Plasma Tumor Necrosis Factor-α Mediate Schizophrenia Symptom Dimensions and Neurocognitive Impairments and Are Inversely Associated with Natural IgM Directed to Malondialdehyde and Paraoxonase 1 Activity. Mol Neurobiol. 2020; 57(5):2333-2345. DOI: 10.1007/s12035-020-01882-w. View

16.

Sirivichayakul S, Kanchanatawan B, Thika S, Carvalho A, Maes M . Eotaxin, an Endogenous Cognitive Deteriorating Chemokine (ECDC), Is a Major Contributor to Cognitive Decline in Normal People and to Executive, Memory, and Sustained Attention Deficits, Formal Thought Disorders, and Psychopathology in Schizophrenia.... Neurotox Res. 2018; 35(1):122-138. DOI: 10.1007/s12640-018-9937-8. View

17.

Sirivichayakul S, Kanchanatawan B, Thika S, Carvalho A, Maes M . A New Schizophrenia Model: Immune Activation is Associated with the Induction of Different Neurotoxic Products which Together Determine Memory Impairments and Schizophrenia Symptom Dimensions. CNS Neurol Disord Drug Targets. 2018; 18(2):124-140. DOI: 10.2174/1871527317666181119115532. View

18.

Maes M, Sirivichayakul S, Kanchanatawan B, Vodjani A . Upregulation of the Intestinal Paracellular Pathway with Breakdown of Tight and Adherens Junctions in Deficit Schizophrenia. Mol Neurobiol. 2019; 56(10):7056-7073. DOI: 10.1007/s12035-019-1578-2. View

19.

Guidara W, Messedi M, Naifar M, Maalej M, Grayaa S, Omri S . Predictive value of oxidative stress biomarkers in drug‑free patients with schizophrenia and schizo-affective disorder. Psychiatry Res. 2020; 293:113467. DOI: 10.1016/j.psychres.2020.113467. View

20.

Maes M, Kanchanatawan B, Sirivichayakul S, Carvalho A . In Schizophrenia, Deficits in Natural IgM Isotype Antibodies Including those Directed to Malondialdehyde and Azelaic Acid Strongly Predict Negative Symptoms, Neurocognitive Impairments, and the Deficit Syndrome. Mol Neurobiol. 2018; 56(7):5122-5135. DOI: 10.1007/s12035-018-1437-6. View